What is Erste Group Bank’s Estimate for BMY FY2026 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Investment analysts at Erste Group Bank lifted their FY2026 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a report issued on Tuesday, March 24th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will earn $6.29 per share for the year, up from their prior forecast of $6.28. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.12 EPS.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

BMY has been the topic of a number of other reports. Morgan Stanley reaffirmed an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Citigroup boosted their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Leerink Partners upped their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research note on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb Trading Down 1.4%

Shares of NYSE:BMY opened at $58.59 on Thursday. The firm has a fifty day moving average of $58.82 and a two-hundred day moving average of $52.20. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $62.89. The firm has a market capitalization of $119.62 billion, a P/E ratio of 16.98, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26.

Institutional Trading of Bristol Myers Squibb

A number of institutional investors and hedge funds have recently made changes to their positions in BMY. Gateway Investment Advisers LLC boosted its stake in Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after purchasing an additional 10,284 shares in the last quarter. CWA Asset Management Group LLC increased its stake in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 30,909 shares in the last quarter. Stephens Inc. AR raised its holdings in shares of Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after buying an additional 32,476 shares during the last quarter. Railway Pension Investments Ltd lifted its position in Bristol Myers Squibb by 3.7% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after buying an additional 40,300 shares in the last quarter. Finally, Norges Bank acquired a new position in Bristol Myers Squibb during the 2nd quarter worth about $1,554,154,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.